K 757
Alternative Names: K-757Latest Information Update: 15 Nov 2024
Price :
$50 *
At a glance
- Originator Kallyope
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Phase I Metabolic disorders; Type 2 diabetes mellitus
Most Recent Events
- 21 Jun 2024 Kallyope completes a phase-I trial in Type 2 diabetes mellitus (Combination therapy) in USA, (PO), (NCT06305351),
- 19 Feb 2024 Kallyope completes a phase II trial in Obesity (Combination therapy, In the elderly, In adults) in USA (PO) (NCT06019559)
- 19 Feb 2024 Kallyope completes phase II trial in Obesity (Monotherapy, In adults, In the elderly) in USA (PO) (NCT06019559)